Defence Therapeutics Signs Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), is pleased to announce that it has signed a Collaboration Agreement with Orano Support SAS on behalf of Orano SA ("Orano"), a world-renowned multinational company, headquartered in Chatillon, France, to develop the next generation of radio-immunoconjugates for radio-immunotherapy using Defence's intracellular targeting technology. The...
2023-03-14 3:15 AM EDT
Defence's Pipeline Advances to Multiple Phase I Clinical Trials
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to update its stakeholders on its completed achievements as well as outlining the future milestones set for 2023. Over the last three years, Defence has been heavily active in developing its...
2023-02-27 3:15 AM EST
Defence Delegates City of Hope to Initiate IND Filing for Its AccuTOX(TM) Cancer Program
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it signed an agreement with City of Hope National Medical Center and Beckman Research Institute of the City of Hope, one of the best and most renowned Cancer Institute Hospital...
2023-02-21 3:15 AM EST
RETRANSMISSION: Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its ARM vaccine manufacturing in preparation of its Phase I clinical trial targeting patients with solid cancer tumors. Defence is continuously striving to exploit its...
2023-02-06 3:15 AM EST
Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors
Vancouver, British Columbia--(Newsfile Corp. - February 3, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its ARM vaccine manufacturing in preparation of its Phase I clinical trial targeting patients with solid cancer tumors. Defence is continuously striving to exploit its...
2023-02-03 5:00 PM EST
Defence Therapeutics and CQDM Fund the Development of a New Cancer Vaccine Platform
Montreal, Quebec--(Newsfile Corp. - February 2, 2023) - In celebration of World Cancer Day, Defence Therapeutics and CQDM are proud to announce the launch of a collaborative research project between Université de Montréal (UdeM), the Lady Davis Institute of the Jewish General Hospital and Defence Therapeutics, a Quebec-based biotechnology company specialized in the development of next-generation vaccines. The funding of this study, totalling $1,359,851, was made possible through a $601,938...
2023-02-02 11:48 AM EST
Defence's Lung Cancer GLP tox Study on Its Intranasal AccuTOX(TM) Formulation Advances
Vancouver, British Columbia--(Newsfile Corp. - January 31, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its GLP studies on a new intranasal AccuTOXTM formulation. This milestone is crucial to initiate a Phase I trial for this drug in the context of lung cancer. AccuTOXTM:...
2023-01-31 3:15 AM EST
Defence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated
Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation of its ARM vaccine candidate in a melanoma model with a cure rate of 60%. Defence used a variant of the AccumTM (the A1) to reprogram innate MSCs into antigen presenting...
2023-01-24 3:15 AM EST
RETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that Defence will attend, from February 7-10, 2023, the Immuno-Oncology 360º "IO360º" premier meeting across all stakeholders in Immuno-Oncology during the 2023 summit at the New-York...
2023-01-23 3:15 AM EST
Defence To Present at The 9th Annual Immuno-Oncology 360 Summit in New-York February 7-10, 2023
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that Defence will attend, from February 7-10, 2023, the Immuno-Oncology 360º "IO360º" premier meeting across all stakeholders in Immuno-Oncology during the 2023 summit at the New-York...
2023-01-20 4:30 PM EST
Defence Accum(TM) Accepted Us Patent to Bolster Its Vaccine Platform Technology IP
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), is pleased to announce that that the United States Patent and Trademark Office (USPTO) has issued a Notice of allowance for their US patent...
2023-01-16 3:15 AM EST
mRNA with Defence's Accum(TM) Program Has Been Initiated
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement in the development of its AccumTM -mRNA vaccine program. This R&D program will not only impact the field of cancer immunotherapy, but it can also be directly applied...
2023-01-10 3:15 AM EST
Breakthrough Results: Defence's Novel AccuTOX(TM) Intranasal Reduced 50% of Cancer Nodules on Animals with Lung Tumors
Vancouver, British Columbia--(Newsfile Corp. - December 20, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, just completed a pre-clinical study using its intranasal formulation of AccuTOXTM in the context of animals with pre-established lung cancer. The study shows that AccuTOXTM administration as a combination...
2022-12-20 3:15 AM EST
Defence's mRNA with Accum(TM) for Cancer Vaccines Update
Vancouver, British Columbia--(Newsfile Corp. - December 15, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is currently working on combining its AccumTM technology with mRNA vaccination as previously announced in press release dated of October 31st, 2022. This R&D program will not only impact the field of...
2022-12-15 3:15 AM EST
Defence Therapeutics Appoints Kwin Grauer to Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the appointment of Mr. Kwin Grauer to its board of directors, effective immediately. Mr. Kwin Grauer, CPA, CA, has more than 20 years' experience operating, buying and selling small...
2022-12-09 3:30 PM EST
Defence Positioned to Begin Its Anti-Cancer AccuTOX(TM) Phase I Trial with Successful Completion of GLP Studies
Vancouver, British Columbia--(Newsfile Corp. - December 6, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful completion of all GLP studies related to its anti-cancer AccuTOXTM molecule. The Company is planning to meet with the FDA in the weeks to come to obtain approval for...
2022-12-06 3:15 AM EST
Defence's Successfull Study on the AccuVAC-PT007 Vaccine Targeting Cervical Cancer
Vancouver, British Columbia--(Newsfile Corp. - November 23, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the successful completion of its Good Laboratory Practice ("GLP") studies on the AccuVAC-PT007 vaccine candidate specifically designed to target cervical cancer. GLP studies conducted...
2022-11-23 3:15 AM EST
Defence Therapeutics Completes Fully-Subscribed Debenture Financing of $2,355,000
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the closing of its previously announced non-brokered private placement of debenture units (the "Units") at a price of $1,000 per Unit for aggregate gross proceeds of $2,355,000 (the...
2022-11-16 6:00 PM EST
mRNA Program: Defence to Apply Its Propriatry Accum(TM) Technology in The Design of Messenger RNA Anti-Cancer Vaccines
Vancouver, British Columbia--(Newsfile Corp. - October 31, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is initiating a new research and development program designed to exploit the AccumTM technology in engineering messenger (m)RNA vaccines targeting cancer. AccumTM is designed for intracellular accumulation...
2022-10-31 3:15 AM EDT
Defence Therapeutics Announces Debenture Financing
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce a non-brokered private placement of debenture units (the "Units") at a price of $1,000 per Unit for aggregate gross proceeds of up to $2,355,000 (the "Offering"). Each Unit will...
2022-10-28 6:00 PM EDT